甘草酸二胺联合前列地尔对大鼠肾间质纤维化的影响

目的 观察甘草酸二胺联合前列地尔对大鼠肾间质纤维化的影响.方法 建立单侧输尿管梗阻(UUO)动物模型,将120只大鼠随机分为假手术组、模型组、甘草酸二胺组、前列地尔组、甘草酸二胺加前列地尔组,每组24只.术后第7、14、21天每组各处死8只大鼠,测定其血清肌酐(CREA)水平,HE染色后观察肾间质变化,免疫组化法观察肾间质转化生长因子-β1(TGF-β1)和结缔组织生长因子(CTGF)的表达,酶联法测定血清TGF-β1、CTGF浓度.结果 模型组在术后第14、21天时血清CREA、TGF-β1、CTGF浓度及TGF-β1、CTGF在肾组织的表达较假手术组均显著增加(P均＜0.01);甘草酸二胺加前列地尔组的肾间质损伤指数及TGF-β1、CTGF在肾间质的表达和血清中TGF-β1、CTGF的浓度均明显低于其他治疗组(P均＜0.01).结论 甘草酸二胺联合前列地尔能改善UUO所致的肾间质纤维化,其机制可能与下调肾组织的TGF-β1、CTGF表达有关.     

复方甘草酸苷联合阿德福韦酯治疗慢性乙型肝炎肝纤维化观察

目的:探讨复方甘草酸苷联合阿德福韦酯治疗慢性乙型肝炎肝纤维化的临床疗效.方法:选择慢性乙型肝炎患者80例,随机分为治疗组和对照组.对照组给予口服阿德福韦酯抗病毒以及维生素等基础治疗,而治疗组在对照组的基础上加用复方甘草酸苷治疗.比较两组治疗前后肝功能谷丙转氨酶(ALT)、谷草转氨酶(AST)和血清中肝纤维化指标透明质酸(HA)、层粘蛋白(LN)、Ⅲ型胶原(PC-Ⅲ)、Ⅳ型胶原(Ⅳ-C)的变化情况.结果:治疗组总有效率ALT( 100.00％)、AST(97.50％)较对照组ALT(77.50％)、AST(74.36％)均明显增加(P＜0.05或0.01);治疗组血清HA、LN、Ⅳ-C、PC-Ⅲ水平较对照组显著下降(P＜0.01).结论:复方甘草酸苷联合阿德福韦酯治疗慢性乙型肝炎肝纤维化明显优于单独应用阿德福韦酯.     

复方甘草酸苷胶囊联合养血生发胶囊治疗斑秃临床疗效观察

目的观察复方甘草酸苷胶囊联合养血生发胶囊治疗斑秃的临床疗效。方法将229例符合入选标准的患者随机分为两组,治疗组119例给予复方甘草酸苷胶囊和养血生发胶囊口服;对照组110例给予养血生发胶囊口服,疗程3个月,观察疗效。结果治疗组有效率为98.3%,对照组有效率为80.0%,差异有显著性（χ2=20.45,P〈0.05）。结论复方甘草酸苷胶囊联合养血生发胶囊治疗斑秃,中西医结合,相辅相成,标本兼治,疗效确切,值得临床推广应用。     

复方甘草酸苷联合阿维A治疗红皮病型银屑病的疗效观察

目的观察阿维A胶囊与复方甘草酸苷胶囊联合治疗红皮病型银屑病的临床疗效。方法62例患者随机均分为两组,治疗组采用复方甘草酸苷联合阿维A治疗;对照组仅单用阿维A治疗。治疗8周后观察疗效。结果治疗组有效率（93．55％）明显高于对照组（80．65％）,差异有统计学意SL（P〈0．05）。结论阿维A胶囊联合复方甘草酸苷胶囊治疗红皮病型银屑病安全、有效,并可减少药物副作用。     

消银胶囊联合复方甘草酸苷治疗寻常型银屑病

目的观察消银胶囊联合复方甘草酸苷治疗寻常型银屑病的临床疗效。方法将本院2009年1月～2011年6月收治的63例寻常型银屑病患者随机分为两组,对照组29例,口服消银胶囊5粒,3次/d,转移因子胶囊3mg,2次/d,同时外用复方氟米松软膏。治疗组34例在此基础上加用复方甘草酸苷片50mg,3次/d,两组均治疗6周观察疗效。结果治疗组治疗后PASI评分为（3.61±2.26）分,低于对照组的（7.3±1.7）分,差异有统计学意义（P〈0.05）;两组患者治疗后的有效率分别为85.3%、65.5%,两组比较差异有统计学意义（P〈0.05）;两组患者治疗前后血、尿常规、肝肾功能等各项指标均未见异常。结论消银胶囊联合复方甘草酸苷治疗寻常型银屑病可明显提高疗效,值得临床应用。     

RP-HPLC法测定复方甘草酸苷注射液中甘草酸苷的含量

目的建立复方甘草酸苷注射液中甘草酸的含量测定方法。方法采用反相高效液相色谱法,C18(4.6mm×250mm,5μm)色谱柱,以0.1mol.L-1的醋酸铵溶液-乙腈-冰醋酸(70∶30∶0.5)为流动相,流速是1.0mL.min-1,检测波长254nm,进样量为20μL。结果甘草酸线性范围为0.05~0.25mg.mL-1(r=0.9999),平均回收率为100.3%(RSD=0.67%),最小检出量2.75ng。结论该方法能准确、可靠地对复方甘草酸苷注射液中的甘草酸进行定量检测,能有效地控制该制剂的质量。     

Glycyrrhizin and glycyrrhetinic acid determination from formalin-fixed tissue

Summary Glycyrrhetinic acid (GA), the main metabolic product of glycyrrhizin (GLY), could be detected in formalin-fixed tissue from a man who died 6 hours after therapeutic administration of a GLY-containing agent. GA was extracted from homogenized formalin-fixed liver tissue and 3 ng GA/g could be detected by HPLC. The extraction from formalin-fixed liver tissue gave the same retention time peak as the GLY control. GA could also be detected by mass spectrometry in the blood sample. This confirms that the man had received a GLY-containing agent for therapeutic use prior to his death and that GA can be determined from formalin-fixed tissue.     

Marked increase of serum hepatitis C virus (HCV) RNA titer during treatment with high-dose prednisolone in a case of polymyositis

A 70-year-old Japanese woman with hepatitis C virus (HCV) infection was diagnosed with polymyositis and treated with high-dose prednisolone (PSL). The serum alanine aminotransferase (ALT) level increased from 78 to 345 U/l 1 week after initiating treatment, although the polymyositis settled promptly. Furthermore, the serum HCV RNA level increased markedly from 110 to 850 kIU/ml 3 weeks after starting treatment. Previously, the patient had suffered an occlusion of the left branch of the retinal vein secondary to hyperviscosity syndrome resulting from Sjögrens syndrome and low-dose PSL treatment had been commenced. The serum HCV RNA and transaminase levels had not increased during this low-dose PSL treatment. Although intensive immunosuppression is necessary as an initial treatment of several collagen diseases including polymyositis, high-dose PSL therapy may markedly augment the serum HCV RNA level and therefore careful observation is necessary in HCV-infected patients.     

Therapeutic basis of glycyrrhizin on chronic hepatitis B

Glycyrrhizin, a major component of a herb (licorice), has been intravenously used for the treatment of chronic hepatitis B in Japan and improves liver function with occasional complete recovery from hepatitis. This substance modifies the intracellular transport and suppresses sialylation of hepatitis B virus (HBV) surface antigen (HBsAg) in vitro. This study was designed to clarify the pharmacological basis for its effectiveness. The structure-bioactivity relationship of glycyrrhizin, glycyrrhetic acid 3-O-monoglucuronide and glycyrrhetic acid was determined, and glycyrrhetic acid was found to be the most active of them. The amounts of three substances bound to the liver were evaluated in guinea pigs after intravenous administration of glycyrrhizin. Glycyrrhizin and glycyrrhetic acid 3-O-monoglucuronide were detected at concentrations of 31.8-1.3 μg/g of liver, but glycyrrhetic acid was not detected. When glycyrrhizin attained these concentrations in the cellular fraction of the PLC/PRF/5 cell culture, it suppressed the secretion of HBsAg as reported previously. These results indicated that glycyrrhizin administered intravenously might bind to hepatocytes at the concentration at which glycyrrhizin could modify the expression of HBV-related antigens on the hepatocytes and suppress sialylation of HBsAg.     

甘草酸抗人肺癌细胞增殖和侵袭作用的研究

目的 :探讨甘草酸对高转移人肺癌细胞 (PGCL3)增殖抑制和抗侵袭的作用。方法 :甘草酸处理PGCL3细胞 ,用细胞增殖抑制试验、软琼脂集落形成试验、侵袭、运动和粘附试验以及组织蛋白酶B活性测定 ,观察细胞增殖和侵袭能力的变化。结果 :甘草酸可降低PGCL3细胞增殖能力 ,并呈剂量依赖性 ,IC50 为 1.83mmol/L ;0 .5mmol/L和 1mmol/L甘草酸能抑制PGCL3细胞的侵袭能力 (P <0 .0 1) ,且有剂量依赖性。抗侵袭作用机理的分析结果显示上述浓度的药物对细胞的运动、粘附及组织蛋白酶B分泌均有明显的抑制作用(P <0 .0 1) ,软琼脂集落形成率也显著降低 (P <0 .0 1)。结论 :甘草酸有抗PGCL3人肺癌细胞增殖和侵袭作用 ,其抗侵袭机理不是对侵袭的某一环节的阻断 ,而是对侵袭各个基本环节都有抑制作用。